Gastrin Hormone Market Overview
The Gastrin Hormone Market was valued at USD 800 Million in 2024 and is expected to remain at USD 800 Million in 2025 before reaching USD 1.5 Billion by 2035, registering a CAGR of 5.9% during the forecast period from 2025 to 2035. Market growth is being supported by the increasing prevalence of gastrointestinal disorders, rising demand for diagnostic testing, advances in research and technology, and expanding pharmaceutical applications of gastrin-related therapies.
Gastrin is an important hormone associated with gastric acid secretion and digestive processes. Its measurement and therapeutic relevance are being studied across a range of gastrointestinal conditions. Increasing attention to gastrin-related disorders is encouraging healthcare providers and research organizations to improve diagnostic approaches and explore potential therapeutic applications.
Technological advances in diagnostic methods are also influencing the market. Improved testing technologies can support more accurate detection of gastrin levels, while developments in biotechnology are creating opportunities for synthetic and recombinant approaches. Personalized medicine is another emerging area, with researchers investigating treatment strategies that can be adapted to individual patient requirements.
North America is anticipated to lead the global market, supported by advanced healthcare infrastructure and strong research and development activity. The region was valued at USD 320 Million in 2024 and is expected to reach USD 600 Million by 2035. Europe remains an important market, while Asia Pacific is witnessing significant growth as healthcare expenditure and awareness of gastrointestinal disorders increase.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=580907
Key Companies in the Global Gastrin Hormone Market
Novartis
Pfizer
Eli Lilly and Company
Mylan N.V.
Teva Pharmaceutical Industries
Biogen
Merck & Co
GlaxoSmithKline
Ferring Pharmaceuticals
Amgen
Johnson & Johnson
Genentech
AbbVie
Sanofi
Boehringer Ingelheim
AstraZeneca
Market Dynamics and Growth Drivers
The increasing prevalence of gastrointestinal disorders is an important factor supporting demand for gastrin-related diagnostics and therapies. Conditions associated with abnormal gastrin levels can require specialized testing, increasing the role of hormone analysis in clinical settings.
Advancements in diagnostic technology are creating additional opportunities. Blood testing, stimulation testing, and endoscopic approaches provide different methods for evaluating gastrin-related conditions. Greater diagnostic accuracy and increased awareness of gastrointestinal health can encourage earlier investigation and treatment.
Research activity is another significant market factor. Pharmaceutical companies, biotechnology firms, and research institutes are examining the biological role of gastrin and its potential therapeutic relevance. These activities can support the development of new treatment approaches and expand applications within gastrointestinal medicine.
Regional Market Insights
North America is anticipated to maintain a leading position because of its advanced healthcare infrastructure, strong pharmaceutical sector, and substantial research activity. Europe is supported by increasing awareness of gastrointestinal disorders and growing interest in personalized medicine. Asia Pacific is experiencing strong growth as healthcare investment rises and the prevalence of digestive diseases increases. South America and the Middle East and Africa are expected to expand at a more moderate pace as healthcare access and infrastructure improve.
Market Segmentation
By application, the market is segmented into Diagnosis, Therapeutics, and Research. Therapeutics represented a major application segment, valued at USD 360 Million in 2024 and projected to reach USD 700 Million by 2035. Diagnosis is also expected to expand as testing technologies improve and early detection receives greater attention.
By end user, the market covers Hospitals, Diagnostic Laboratories, and Research Institutes. Hospitals represent an important clinical setting, while diagnostic laboratories support accurate measurement of gastrin levels and research institutes contribute to studies of gastrin biology and therapeutic applications.
By test type, the market includes Blood Test, Stimulation Test, and Endoscopic Test. Blood testing remains an important method for assessing gastrin levels, while stimulation testing can support the evaluation of specific gastrointestinal disorders.
By distribution channel, the market includes Direct Sales, Distribution Partnerships, and Online Sales. The development of digital purchasing channels is creating additional opportunities for market access.
Recent Developments and Market Trends:
Novartis announced a strategic partnership in July 2025 with a GI-focused biotechnology company to co-develop gastrin pathway modulators.
Pfizer announced the acquisition of GastrinTech in June 2025 to strengthen its gastrin receptor modulation capabilities.
Eli Lilly and Company announced a gastrin-pathway targeted product launch in April 2025 for gastric disorders.
Personalized medicine is becoming increasingly relevant to gastrin-related therapeutic research.
Improved diagnostic technologies are supporting more accurate gastrin hormone measurement.
Biotechnology advancements are creating opportunities for synthetic and recombinant gastrin production.
Reasons to Buy the Report:
Understand the projected development of the Gastrin Hormone Market through 2035.
Analyze the market by application, end user, test type, distribution channel, and region.
Evaluate the impact of gastrointestinal disorders on market demand.
Review the competitive landscape and major companies operating in the market.
Assess opportunities associated with biotechnology, diagnostics, and personalized medicine.
Future Outlook:
The Gastrin Hormone Market is expected to expand steadily through 2035 as gastrointestinal disorders, diagnostic requirements, and research activity continue to influence demand. Future development is likely to focus on improved diagnostic technologies, targeted therapeutic approaches, biotechnology-based production, and personalized medicine. Increasing healthcare investment in Asia Pacific and other developing markets may also broaden access to gastrin-related diagnostics and treatments.
➤➤Explore Our Latest Related Reports:
